Access the full text.
Sign up today, get DeepDyve free for 14 days.
The rates of herpes simplex virus (HSV) infection are rising, the highest prevalence being in the group infected with the human immunodeficiency virus (HIV). We review the relation between these 2 infections. The presence of genital ulcers increases the transmission of HIV, and the presence of HIV adversely affects the natural history of HSV infection. The detection and treatment of sexually transmitted diseases such as genital herpes actually decrease the rates of HIV infection in groups studied. The treatment of HSV in persons with HIV is challenging because the incidence of immunosuppression increases. Acyclovir resistance is more common in this group, but acyclovir use may prolong survival in some HIV-seropositive patients. Further studies are needed to determine whether persons with HIV disease should routinely be given HSV-specific therapy.Herpes simplex viruses (HSVs) are the most common cause of genital ulcer disease worldwide.Genital herpes is the most frequent sexually transmitted disease (STD) among persons seropositive for the human immunodeficiency virus (HIV),and most persons seropositive for HSV type 2 (HSV-2) have an intermittent reactivation of the virus on mucosal surfaces.In addition, disruption of the epithelial barrier and inflammation of HSV genital ulcers appear to increase the risk of HIV transmission. Acute or reactivated HSV infection may stimulate HIV replication, leading to the progression of HIV disease.On the other hand, HIV-induced immunosuppression results in alterations in the natural history of HSV. More severe HSV outbreaks and more frequent viral shedding are common in persons coinfected with HIV and HSV compared with those without HIV infection.The treatment of HSV can be more challenging in HIV-infected patients. Higher doses of antiviral drugs may be required, and persons infected with HIV have an increased incidence of acyclovir-resistant HSV.This appears unrelated to acyclovir exposure because resistance is found in patients with no previous exposure to acyclovir, and rates of acyclovir resistance are lower in patients taking suppressive doses of acyclovir compared with those receiving therapeutic doses of the drug.In fact, a survival benefit has been shownwhen acyclovir is added to the medical regimen of HIV-positive patients. Further evidencesuggests that HSV suppression with acyclovir indirectly lowers the HIV load, which is important in predicting the disease progression and response to antiretroviral therapy. These relationships may have implications for HIV control efforts, and intervening in these virus-virus interactions may modulate the progression of HIV infection. A consensus regarding the antiviral suppression of HSV in HIV-infected patients has not yet been reached. Further studies are needed to determine if HSV-specific antiviral therapy should be routinely added to the medical regimen of patients coinfected with HSV and HIV.PREVALENCE OF COINFECTION WITH HSV AND HIVDespite the widespread message in the 1980s and 1990s of the importance of safe sex in response to the HIV epidemic, the prevalence of HSV-2 infection in the United States has increased by 30% since 1976.Between 1988 and 1994, 45 million people were estimatedto be seropositive for HSV-2. This corresponds to 1 of 5 people older than 12 years. The rates of HSV seropositivity in HIV-infected persons are even higher and vary geographically. A studyin Baltimore, Md, showed HSV-2 seroprevalence of 81% among HIV-positive homosexual or bisexual men. In a study of HIV-positive heterosexual persons in south London, England, 43% of women and 38% of men had genital ulcers caused by HSV, antigens of which were detected by enzyme-linked immunosorbent assay.Serologic tests would have likely revealed higher percentages of HSV seropositivity. The prevalence of coinfection with HIV and HSV in Haitian women is 88%,and in prostitutes from Zaire, the prevalence is 95%.INCREASED TRANSMISSION OF HIV IN THE PRESENCE OF HSVMany studieshave found an association between the acquisition of HIV and the presence of genital lesions in the source contact. Other studieshave specifically classified HSV as the cause of such genital lesions. It is estimatedthat ulcerative and nonulcerative STDs increase the risk of HIV transmission 3 to 5 times.An increased viral load and the proximity of virions to cutaneous surfaces are factors that may lead to the increased transmission of HIV in the presence of HSV. Genital ulcers from HSV may facilitate the transmission of HIV through the reduced epithelial barrier and infiltration of CD4+lymphocytes in herpetic lesions that are possible targets for HIV attachment and entry.In addition, it is hypothesizedthat the antigenic stimulation of mucosal sites by the reactivation of HSV can increase HIV type 1 (HIV-1) replication on mucosal surfaces. Tetanus toxoid, influenza, and pneumococcal immunization is already knownto transiently increase the plasma HIV-1 RNA concentration through the activation of T cells from antigenic stimulation. Schacker et algave further evidence to support the hypothesis that genital herpes infection increases the efficiency of the sexual transmission of HIV-1. In their study, HIV-1 virions were consistently detected in genital ulcers caused by HSV-2 in HIV-seropositive men. In addition, the burst of HIV-1 virions that accompanies recurrent genital lesions may help explain the intermittent nature of the transmission of HIV-1 among stable sexual partners.INTERVENTIONStudieshave shown that the treatment and prevention of STDs reduce HIV transmission. In rural Tanzania, improved STD treatment (including genital ulcers) reduced the HIV incidence by about 42% during 2 years of follow-up.Mertz et alstudied the etiology of genital ulcers and the prevalence of HIV coinfection in 10 US cities, finding an average of 6% HIV seropositivity among patients with genital ulcers. They concluded that persons with genital ulcers should be the focus of HIV prevention activities.ACCELERATED PROGRESSION OF HIV DISEASE IN THE PRESENCE OF HSVThe plasma HIV load is important in predicting disease progression, the response to antiretroviral therapy, or both.In clinically latent HIV infection, acute or reactivated HSV infection may be involved in stimulating HIV replication, resulting in a progression to the acquired immunodeficiency syndrome (AIDS).A study by Mole et aldemonstrated increased HIV RNA levels during active HSV infection. During an acute outbreak of HSV infection, the plasma HIV load increased a median of 3.4-fold, and in some patients, postoutbreak levels remained above preoutbreak baseline levels. The episode of acute HSV infection also increased HIV transcription, as evidenced by increased intracellular HIV gagmessenger RNA. Kucera et alreport that coinfection of human CD4+cells with HSV and HIV results in a unidirectional accelerated replication of HIV.Similarly, Heng et alfound that the up-regulation of HIV-1 expression was induced by HSV, which may translate to increased plasma HIV-1 RNA levels. Their study documented in vivo reciprocal enhancement of viral replication associated with the coinfection of keratinocytes and macrophages by HIV-1 and HSV type 1 in patients with AIDS and nongenital HSV lesions. This observation may be evidence of the importance of including antiherpetic drugs as part of the overall treatment of patients with AIDS to avoid the excessive replication of HIV-1 in both CD4+-dependent and -independent targets.ALTERATION IN NATURAL HISTORY AND RESPONSE TO THERAPY FOR HSV IN THE PRESENCE OF HIVClinical Manifestations and Viral Shedding of HSVHerpes infections are more severe in immunocompromised patients. Multiple necrotic ulcers may appear in atypical locations. The outbreaks may progress to more extensive and more persistent lesions.There may be more frequent recurrences or chronic and nearly continuous ulcerations as HIV-related immunosuppression progresses.Herpes simplex virus may also cause esophagitis and, rarely, pneumonitis or hepatitis in patients with AIDS.The prevalence of HSV-2 shedding is nearly 4 times greater in HIV-seropositive women than in HIV-seronegative women.Seventy-nine percent of viral shedding among HIV-seronegative women is asymptomatic, and overall shedding increases significantly as the CD4+cell count decreases. Asymptomatic perianal shedding of HSV is common in patients with AIDS,even in those without a history of perianal lesions. Schacker et alfound that 81% of HIV- and HSV-2–seropositive men shed HSV-2 and that most shedding was asymptomatic.Treatment of HSV Infection in HIV-Seropositive PatientsA meta-analysisof 8 controlled randomized trials showed that acyclovir therapy offered a substantial survival benefit in patients with HIV infection. A survival advantage was seen specifically in studieswith high incidences of clinical herpesvirus infections. One possible explanation offered is that reducing the incidence of HSV and varicella-zoster virus infections may suppress bursts of HIV replication occurring during active herpesvirus infections. These studies were done before the availability of viral load measurement (HIV RNA), which may have offered more relevant prognostic information. Also, this analysis was conducted in the era of zidovudine monotherapy, preceding the widespread use of triple antiretroviral therapy. Apolonio et alanalyzed survival rates in a cohort of HIV-1–infected men with a CD4+lymphocyte count of less than 0.05×109/L (50/µL). One of the strongest factors affecting mortality included concurrent acyclovir and zidovudine use. The suppression of HSV reactivation may offer an additional benefit in reducing ongoing T-cell activation.Recently, HIV-infected patients receiving suppressive acyclovir therapy were foundto have lower HIV RNA levels, as determined by reverse transcription–polymerase chain reaction, than patients not taking suppressive acyclovir.Although their use is specifically approved by the Food and Drug Administration only in immunocompetent persons, famciclovir and valacyclovir hydrochloride appear safe and well tolerated for short- and long-term use in immunocompromised patients, including HIV-positive persons.Valacyclovir is effective in preventing HSV recurrences, and study resultsindicate that taking valacyclovir hydrochloride, 500 mg twice a day, offers better protection in HIV-positive patients than using acyclovir. Famciclovir is effective in suppressing symptomatic and asymptomatic HSV shedding and recurrences in HIV-infected patients.Total HSV-2 shedding is decreased 81%, and the frequency of genital signs and symptoms is decreased 65%.Suppressive dosing with famciclovir (500 mg twice a day) has the same effectiveness as the use of acyclovir (400 mg 5 times a day) at a more convenient dosing regimen.Most of the patients who participated in suppression trials were taking highly active antiretroviral therapy.The adverse effects of acyclovir, famciclovir, and valacyclovir are similar to those observed in immunocompetent persons. There is a possible relation between receiving high doses of valacyclovir hydrochloride (8 g/d for 1 year) and the incidence of thrombotic microangiopathy in immunocompromised patients.Recent studiesof the use of famciclovir and valacyclovir in immunocompromised patients have not reported any cases of thrombotic microangiopathy.Although HSV outbreaks may be less frequent and less severe in patients taking highly active antiretroviral therapy, these patients continue to have outbreaks and asymptomatic viral shedding. Additional large studies are needed to determine if antiviral drugs specific for HSV should be routinely used in HIV-positive patients.Acyclovir-Resistant HSVThe Centers for Disease Control and Prevention recently reportedpreliminary results from a national surveillance of acyclovir-resistant HSV. Of 1218 HSV isolates tested, 99.2% were sensitive to acyclovir. Of 140 isolates from HIV-positive patients, 6.4% were resistant to acyclovir. Resistance to acyclovir is caused by mutations in the viral thymidine kinase or DNA polymerase genes. These mutations result in decreased or absent HSV thymidine kinase production, altered affinity of the thymidine kinase for acyclovir triphosphate, or altered affinity of the HSV DNA polymerase for acyclovir triphosphate.Acyclovir-resistant strains of HSV have been recovered from patients who have never been treated with acyclovir.In addition, the frequency of in vitro resistance has not changed from the time before the availability of acyclovir and does not appear increased among patients who received daily suppressive therapy for several years.Resistant HSV strains are more common in patients who receive therapeutic vs prophylactic antiviral therapy.Prophylactic HSV treatment reduces the number of replicating viruses,which is thought to decrease the likelihood of viral mutations. The increased incidence of acyclovir resistance in HIV-infected patients is probably due to an increased replication of HSV and decreased immunity in these patients. Therefore, taking anti-HSV drugs may likely decrease resistance by decreasing HSV replication.Most acyclovir-resistant HSV isolates are susceptible to antiviral drugs that do not require activation by thymidine kinase.Foscarnet sodium (40 mg/kg intravenously every 8 hours) is approved by the Food and Drug Administration for the treatment of acyclovir-resistant HSV. Foscarnet is a pyrophosphate analogue that directly inhibits HSV DNA polymerase without requiring activation. Foscarnet also selectively inhibits in vitro the reverse transcriptase of HIV. Its use is limited, however, because it requires parenteral infusion and has substantial renal toxic effects.Cidofovir is an antiviral agent that is phosphorylated to its active metabolite by host cellular enzymes rather than requiring virus-specific thymidine kinase. Cidofovir is a nucleotide analogue of deoxycytidine monophosphate with broad-spectrum anti–DNA virus activity. Cidofovir gel (0.3% or 1% gel daily for 5 days) has been evaluatedfor the treatment of acyclovir-unresponsive mucocutaneous HSV infection in patients with AIDS. Substantial benefits in lesion healing, virologic effect, and pain reduction are seen with cidofovir therapy.The drug has yet to receive approval and is not commercially available in a topical formulation.CONCLUSIONSThe incidence of HSV infection continues to increase, and it affects most people seropositive for HIV. There is convincing evidence that the genital ulcers caused from HSV increase the risk of transmission of HIV. The treatment and prevention of STDs such as genital herpes may even help prevent HIV infection. More rigorous study designs are needed to confirm these possibilities. Recurrent HSV infection may accelerate the progression of HIV disease, and certainly, HIV-induced immunosuppression alters the reactivation of HSV. Antiviral therapies are safe and effective for episodic and suppressive treatment of HSV in HIV-infected persons; furthermore, suppressive therapy appears to offer a survival benefit in such persons. Since HSV reactivation and viral shedding exist, although to a lesser extent, in the less than 10% of HIV-infected persons in the world receiving highly active antiretroviral therapy, these persons may also benefit from suppressive therapy of HSV. The incidence of acyclovir resistance is increased in HIV-infected persons, although apparently not because of exposure to anti-HSV therapies but, rather, because of increased viral replication due to decreased immunity. Further studies are needed to determine if HSV-specific antiviral therapy should be routinely added to the medical regimen of patients coinfected with HSV and HIV.MSchomogyiAWaldLCoreyHerpes simplex virus-2 infection: an emerging disease?Infect Dis Clin North Am.1998;12:47-61.NO'FarrellSJToveyHigh cumulative incidence of genital herpes amongst HIV-1 seropositive heterosexuals in south London.Int J STD AIDS.1994;5:415-418.MAugenbraunJFeldmanKChirgwinIncreased genital shedding of herpes simplex virus type 2 in HIV-seropositive women.Ann Intern Med.1995;123:845-847.TSchackerHLHuDMKoelleFamciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons: a double-blind, placebo-controlled trial.Ann Intern Med.1998;128:21-28.MCYHengSYHengSGAllenCo-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus-1.Lancet.1994;343:255-258.MReyesJGraberWReevesAcyclovir-resistant HSV: preliminary results from a national surveillance system.Paper presented at: International Conference on Emerging Infectious Diseases; March 10, 1998; Atlanta, Ga. Abstract.DWBarrySNLehrmanMNEllisClinical and laboratory experience with acyclovir-resistant herpes viruses.J Antimicrob Chemother.1986;18(suppl B):75-84.CMcLarenLCoreyCDekketDWBarryIn vitro sensitivity to acyclovir in genital herpes simplex viruses from acyclovir-treated patients.J Infect Dis.1983;148:868-875.SNLehrmanJMDouglasLCoreyDWBarryRecurrent genital herpes and suppressive oral acyclovir therapy: relation between clinical outcome and in-vitro drug sensitivity.Ann Intern Med.1986;104:786-790.KHFifeCSCrumpackerGJMertzELHillGSBooneRecurrence and resistance patterns of herpes simplex virus following cessation of ≥6 years of chronic suppression with acyclovir: Acyclovir Study Group.J Infect Dis.1994;169:1338-1341.JAEnglundMEZimmermanEMSwierkoszJLGoodmanDRSchollHHBalfour JrHerpes simplex virus resistant to acyclovir: a study in a tertiary care center.Ann Intern Med.1990;112:416-422.GBoivinAEriceDDCraneDLDunnHHBalfour JrAcyclovir susceptibilities of herpes simplex virus strains isolated from solid organ transplant recipients after acyclovir or ganciclovir prophylaxis.Antimicrob Agents Chemother.1993;37:357-359.JPIoannidisACCollierDACooperClinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data.J Infect Dis.1998;178:349-359.TSchackerHLuJZehMShaughnessyLCoreyHSV suppression is associated with a significant decrease in plasma levels of HIV.Program and abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections; May 20, 1998; Alexandria, Va. Abstract 260.DTFlemingGMMcQuillanREJohnsonHerpes simplex virus type 2 in the United States, 1976 to 1994.N Engl J Med.1997;337:1105-1111.EWHook IIIROCannonAJNahmiasHerpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals.J Infect Dis.1992;165:251-255.RBoulosAJRuffANahmiasHerpes simplex virus type 2 infection, syphilis, and hepatitis B virus infection in Haitian women with human immunodeficiency virus type 1 and human T lymphotropic virus type 1 infections: the Johns Hopkins University (JHU)/Centre pour le Developpement et la Sante (CDS) HIV Study Group.J Infect Dis.1992;166:418-420.RWRyderMNdiluSEHassigHeterosexual transmission of HIV-1 among employees and their spouses at two large businesses in Zaire.AIDS.1990;4:725-732.MWOtten JrAAZaidiTAPetermanRTRolfsJJWitteHigh rate of HIV seroconversion among patients attending urban sexually transmitted disease clinics.AIDS.1994;8:549-553.ASLatifDAKatzensteinMTBassettSHoustonJCEmmanualEMarowaGenital ulcers and transmission of HIV among couples in Zimbabwe.AIDS.1989;3:519-523.Study GroupEuropeanRisk factors for male to female transmission of HIV.BMJ.1989;298:411-415.NClumeckHTaelmanPHermansPPiotMSchoumacherSDe WitA cluster of HIV infection among heterosexual people without apparent risk factors.N Engl J Med.1989;321:1460-1462.DWCameronJNSimonsenLJD'CostaFemale to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men.Lancet.1989;2:403-407.KGCastroSLiebHWJaffeTransmission of HIV in Belle Glade, Florida: lessons for other communities in the United States.Science.1988;239:193-197.WEStammHHHandsfieldAMRompaloRLAshleyPLRobertsLCoreyThe association between genital ulcer disease and acquisition of HIV infection in homosexual men.JAMA.1988;260:1429-1433.LAKingsleyJArmstrongARahmanMHoCRinaldo JrNo association between herpes simplex virus type-2 seropositivity or anogenital lesions and HIV seroconversion among homosexual men.J Acquir Immune Defic Syndr Hum Retrovirol.1990;3:773-779.CGHayesCRManalotoVBasaca-SevillaEpidemiology of HIV infection among prostitutes in the Philippines.J Acquir Immune Defic Syndr Hum Retrovirol.1990;3:913-920.SDHolmbergJAStewartARGerberPrior herpes simplex virus type 2 infection as a risk factor for HIV infection.JAMA.1988;259:1048-1050.MVanRadenRKaslowLKingsleyThe role of ulcerative genital diseases in promoting acquisition of HIV-1 by homosexual men.Programs and abstracts of the Fifth International AIDS Conference; 1989; Montreal, Ontario. Abstract Th.A.O.17.RMGreenblattSALukehartFAPlummerGenital ulceration as a risk factor for human immunodeficiency virus infection.AIDS.1988;2:47-50.IKeetFLeeGvan GriensvenHerpes simplex virus type 2 and other genital ulcerative infections as a risk factor for HIV-1 acquisition.Genitourinary Med.1990;66:330-333.EETelzakMAChiassonPJBevierRLStoneburnerKGCastroHWJaffeHIV-1 seroconversion in patients with and without genital ulcer disease: a prospective study.Ann Intern Med.1993;119:1181-1186.JNWasserheitEpidemiological synergy: interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases.Sex Transm Dis.1992;29:61-77.ALCunninghamRRTurnerACMillerMFParaTCMeriganEvolution of recurrent herpes simplex lesions: an immunohistologic study.J Clin Invest.1985;75:226-233.DMKoelleHAbboAPeckKZiegweidLCoreyDirect recovery of herpes simplex virus (HSV)-specific T lymphocyte clones from recurrent genital HSV-2 lesions.J Infect Dis.1994;169:956-961.TSchackerAJRyncarzJGoddardKDiemMShaughnessyLCoreyFrequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men.JAMA.1998;280:61-66.SKStanleyMAOstrowskiJSJustementEffect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1.N Engl J Med.1996;334:1222-1230.WAO'BrienKGrovit-FerbasANamaziHuman immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination.Blood.1995;86:1082-1089.ZRiosEORiosMIGarciaChanges in viral expression and cytokine profile induced by a polyantigenic immunomodulator in HIV-infected peripheral blood mononuclear cells.Cell Mol Biol (Noisy-le-grand).1995;41(suppl 1):S93-S101.BBrichacekSSwindellsENJanoffSPirruccelloMStevensonIncreased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine.J Infect Dis.1996;174:1191-1199.TAPetermanRLStoneburnerJRAllenHWJaffeJWCurranRisk of human immunodeficiency virus transmission from heterosexual adults with transfusion-associated infections [published correction appears in JAMA.1989;262:502].JAMA.1988;259:55-58.HGrosskurthFMoshaJToddImpact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial.Lancet.1995;346:530-536.RSHanenbergWRojanapithayakornPKunasolDCSokalImpact of Thailand's HIV-control programme as indicated by the decline of sexually transmitted diseases.Lancet.1994;344:243-245.KENelsonDDCelentanoSEiumtrakolChanges in sexual behavior and a decline in HIV infection among young men in Thailand.N Engl J Med.1996;335:297-303.KJMertzDTreesWCLevineEtiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities: The Genital Ulcer Disease Surveillance Group.J Infect Dis.1998;178:1795-1798.JWMellorsCRRinaldo JrPGuptaRMWhiteJAToddLAKingsleyPrognosis in HIV-1 infection predicted by the quantity of virus in plasma [published correction appears in Science.1997;275:14].Science.1996;272:1167-1170.DAKatzensteinSMHammerMDHughesThe relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter: AIDS Clinical Trials Group Study 175 Virology Study Team [published erratum appears in N Engl J Med.1997;337:1097].N Engl J Med.1996;335:1091-1098.MPGoldenSKimSMHammerActivation of human immunodeficiency virus by herpes simplex virus.J Infect Dis.1992;166:494-499.PDGriffithsStudies to define viral cofactors for human immunodeficiency virus.Infect Agents Dis.1992;1:237-244.LMoleSRipichDMargolisMHolodniyThe impact of active herpes simplex virus infection on human immunodeficiency virus load.J Infect Dis.1997;176:766-770.LSKuceraELeakeNIyerDRabenQNMyrvikHuman immunodeficiency virus type 1 (HIV-1) and herpes simplex virus type 2 (HSV-2) can coinfect and simultaneously replicate in the same human CD4+cell: effect of coinfection on infectious HSV-2 and HIV-1 replication.AIDS Res Hum Retroviruses.1990;6:641-647.GVQuinnan JrHMasurAHRookHerpesvirus infections in the acquired immune deficiency syndrome.JAMA.1984;252:72-77.FPSiegalCLopezGSHammerSevere acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions.N Engl J Med.1981;305:1439-1444.JAMaierABergmanMGRossAcquired immunodeficiency syndrome manifested by chronic primary genital herpes.Am J Obstet Gynecol.1986;155:756-758.LCoreyAWaldGenital herpes.In: Holmes K, ed. Sexually Transmitted Diseases.New York, NY: McGraw Hill Book Co; 1999:285-312.EKBagdadesDPillaySBSquireCO'NeilMAJohnsonPDGriffithsRelationship between herpes simplex virus ulceration and CD4+cell counts in patients with HIV infection.AIDS.1992;6:1317-1320.JANelsonPGhazalCAWileyRole of opportunistic viral infections in AIDS.AIDS.1990;4:1-10.CSPannutiMCristinaDSFinckAsymptomatic perianal shedding of herpes simplex virus in patients with acquired immunodeficiency syndrome.Arch Dermatol.1997;133:180-183.EGApolonioDRHooverYHePrognostic factors in human immunodeficiency virus–positive patients with a CD4+lymphocyte count <50/µL.J Infect Dis.1995;171:829-836.LLockeCYoungRSaltzmanFamciclovir safety experience in long-term treatment and in immunocompromised patients.Paper presented at: 8th International Congress on Infectious Diseases; May 15, 1998; Boston, Mass. Abstract.ALawrenceABellValaciclovir for prevention of recurrent herpes virus infection in HIV-infected individuals: a double-blind controlled trial.Poster presentation at: 8th European Congress of Clinical Microbiology and Infectious Diseases; October 27, 1997; Lausanne, Switzerland.ABurnsideRPrestonRCrannCYoungFamciclovir for suppression of recurrent genital herpes in HIV-infected patients.Paper presented at: 36th Annual Meeting of the Infectious Diseases Society of America; November 14, 1998; Denver, Colo.GFrechetteBRomanowsiEfficacy and safety of famciclovir for the treatment of HSV infection in HIV+ patients.Paper presented at: Sixth Annual Canadian Conference on HIV/AIDS Research; July 16, 1997; Ottawa, Ontario.WRBellJDChulayJEFeinbergManifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204).Medicine (Baltimore).1997;76:369-380.RFAmbinderWHBurnsPSLietmanRSaralProphylaxis: a strategy to minimise antiviral resistance.Lancet.1984;1:1154-1155.PAChatisCHMillerLESchragerCSCrumpackerSuccessful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with the acquired immunodeficiency syndrome.N Engl J Med.1989;320:297-300.KSErlichJMillsPChatisAcyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome.N Engl J Med.1989;320:293-296.SANorrisHAKesslerKHFifeSevere, progressive herpetic whitlow caused by an acyclovir-resistant virus in a patient with AIDS [letter].J Infect Dis.1988;157:209-210.MMYouleDAHawkinsPCollinsAcyclovir-resistant herpes in AIDS treated with foscarnet [letter].Lancet.1988;2:341-342.JLalezariTSchackerJFeinbergA randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS.J Infect Dis.1997;176:892-898.Accepted for publication June 4, 1999.Corresponding author: Stephen K. Tyring, MD, PhD, Department of Dermatology, University of Texas Medical Branch, 301 University Blvd, Rte 1070, Galveston, TX 77555.
JAMA Dermatology – American Medical Association
Published: Nov 1, 1999
Access the full text.
Sign up today, get DeepDyve free for 14 days.